Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Researchers' work from Progenics Pharmaceuticals, Inc. focuses on cancer vaccines
July 25th, 2007
Data detailed in "A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses" have been presented. According to recent research from the United States, "Prostate-specific membrane antigen (PSMA) is an attractive target for active immunotherapy. Alphavirus vaccines have shown promise in eliciting immunity to tumor antigens." "This study investigated the immunogenicity of alphavirus vaccine replicon particles (VRP) that encode PSMA (PSMA-VRP). Cells were infected with PSMA-VRP and evaluated for PSMA expression and folate hydrolase activity. Mice were immunized s.c. with PSMA-VRP or purified PSMA protein....
Source: Vaccine Weekly (2007-07-25)
|
